| Basics |
Verona Pharma
Verona Pharma PLC develops drugs for respiratory diseases. Its products mainly include anti-inflammatory agents and bronchodilators.
|
| IPO Date: |
April 24, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$8.92B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.41 | 2.83%
|
| Avg Daily Range (30 D): |
$1.05 | 1.13%
|
| Avg Daily Range (90 D): |
$1.53 | 2.22%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
5.21M |
| Avg Daily Volume (90 D): |
2.64M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
186 |
| Avg Trade Size (Sh.) (90 D): |
123 |
| Institutional Trades |
| Total Inst.Trades: |
2,029 |
| Avg Inst. Trade: |
$2.8M |
| Avg Inst. Trade (30 D): |
$5.4M |
| Avg Inst. Trade (90 D): |
$4.4M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.45M |
| Avg Closing Trade (30 D): |
$5.93M |
| Avg Closing Trade (90 D): |
$4.46M |
| Avg Closing Volume: |
51.69K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.02
|
$-.07
|
|
Diluted EPS
|
|
$-.02
|
$-.07
|
|
Revenue
|
$
|
$ 76.26M
|
$ 5.62M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -16.32M
|
$ -42.96M
|
|
Operating Income / Loss
|
$
|
$ -10.32M
|
$ -40.67M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 1.66M
|
$ -68.56M
|
|
PE Ratio
|
|
|
|
|
|
|
